Camurus AB: Camurus' Full Year Report 2024

"Excellent finish to the year with strong growth and high profitability"

Fourth quarter and full year summary

October - December

• Total revenues grew 48% (44% at CER¹) to SEK 553 (375) million
• Sales of Buvidal^® increased 28% (26% at CER¹) to SEK 469 (366) million. Compared to the previous quarter, the increase was 11% (9% at CER¹).
• Brixadi^® royalties increased 990% to SEK 83 (8) million. Compared to the previous quarter, the increase was 43%.
• Profit before tax increased by SEK 204 million to SEK 186 (-18) million
• The cash position at the end of the quarter was SEK 2.9 (1.2) billion
• FDA issued a Complete Response Letter for CAM2029 for treatment of acromegaly relating to a cGMP inspection of a third-party manufacturing facility
• The European Commission granted Orphan Drug Designation to CAM2029 for treatment of autosomal dominant polycystic liver disease
• Clinical Trial authorization received for a semaglutide once-monthly depot (CAM2056)

January - December

• Total revenues grew 9% to SEK 1,868 (1,717) million. Adjusted for one-time milestone revenues in 2023², the increase was 42% (41% at CER¹).
• Sales of Buvidal increased 27% (27% at CER¹) to SEK 1,654 (1,299) million
• Brixadi royalties increased to SEK 212 (9) million
• Profit before tax increased 4% to SEK 553 (549) million. Excluding one-time revenues², the increase was SEK 409 million, 286%.

Significant events after the period

• Camurus announced preliminary 2024 earnings, above previous full year estimate

Financial outlook 2025

• Total revenues SEK 2.7 to 3.0 billion, +45% to +61% vs. 2024
• Profit before tax SEK 0.9 to 1.2 billion, +63% to +117% vs. 2024

1. At constant exchange rate
2. Excluding one-time milestones related to the Brixadi approval by the FDA in the US in 2023

Fredrik Tiberg, President and CEO:
"Camurus ended 2024 with a very solid fourth quarter, growing 48 percent year on year, driven by increasing Buvidal^® sales and royalty revenues from Brixadi^® in the US. Due to strong financial performance, results for the quarter and full year exceeded previous estimates. In the development pipeline, a Complete Response Letter (CRL) was issued by the FDA for the CAM2029 New Drug Application for acromegaly in the US, solely related to observations during a cGMP inspection at a third-party manufacturer. The Marketing Authorization Application for CAM2029 in the EU progressed according to plan during the quarter, alongside pivotal clinical studies of CAM2029 in neuroendocrine tumors and polycystic liver disease. In the early pipeline, a clinical study of our monthly semaglutide depot (CAM2056) was initiated in participants with overweight or obesity."

Audiocast
Financial analysts and media are invited to attend a telephone conference and presentation of the results today at 2.00 pm (CET). The conference call can also be followed by a link on www.camurus.com or via external link: https://financialhearings.com/event/51936

For more information:
Fredrik Tiberg, President and CEO
Tel. [phone]
[e-mail]

Fredrik Joabsson, Chief Business Development Officer
Tel. [phone]
[e-mail]

About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal^® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.

This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation and to the Securities Markets Act. The information was submitted for publication, through the agency of the chief executive officer, at 07.00 am CET on 13 February, 2025.